The proposed reform of the Medical Device Regulation and its implications for AI-enabled medical devices in the EU

Nature
Read full story· 24 min
The European Commission proposed amendments in December 2025 to reform the EU Medical Device Regulation (MDR) and related laws to reduce regulatory burdens and overlaps, aiming to foster innovation in AI-enabled medical devices. Despite improvements, the reforms leave unresolved challenges for innovative AI medical devices, impacting development and market access.

What happened

In December 2025, the European Commission put forward a set of amendments to the Medical Device Regulation (MDR), the In Vitro Diagnostic Medical Devices Regulation (IVDR), and the AI Act (AIA) in the European Union. The goal was to reduce regulatory complexity and documentation requirements, particularly for AI-enabled medical devices. The proposal, known as MDR 2.0, was intended to address overlapping rules and streamline the approval process. Despite these efforts, certain challenges for innovative AI medical devices remain unresolved, affecting how these products are developed and brought to the EU market.

Key details

  • The MDR 2.0 proposal was published in December 2025.
  • The reforms target the MDR, IVDR, and AI Act in a single legislative package.
  • Manufacturers have reported delays, cancellations, and discontinuations of medical devices due to regulatory burdens.
  • The Digital Omnibus on AI, adopted in July 2026, delayed high-risk AI device requirements to August 2028.
  • The European Commission must adopt delegated acts related to these reforms by August 2, 2027.

Why it matters

Manufacturers of AI-enabled medical devices in the EU face ongoing regulatory hurdles, which can increase costs, delay product launches, and limit access to innovative technologies for patients. The reforms offer some relief by aiming to simplify compliance, but unresolved overlaps and requirements mean companies still encounter significant barriers. As a result, some manufacturers may reconsider their presence in the EU market, and patients could experience reduced availability of new medical technologies.


More in Healthcare